Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance. The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to consider the minimum acceptable performance of BBM tests for clinical use. Amyloid PET status was identified as the reference standard. For use as a triaging test before subsequent confirmatory tests such as amyloid PET or CSF tests, the BBM Workgroup recommends that a BBM test has a sensitivity of ≥90% with a specificity of ≥85% in primary care and ≥75-85% in secondary care depending on the availability of follow-up testing. For use as a confirmatory test without follow-up tests, a BBM test should have performance equivalent to that of CSF tests - a sensitivity and specificity of ~90%. Importantly, the predictive values of all biomarker tests vary according to the pre-test probability of amyloid pathology and must be interpreted in the complete clinical context. Use of BBM tests that meet these performance standards could enable more people to receive an accurate and timely Alzheimer disease diagnosis and potentially benefit from new treatments.

What this study adds

Evidence grade: Moderate

An expert workgroup of the Global CEO Initiative on Alzheimer's Disease set minimum accuracy targets for blood tests of amyloid, judged against amyloid PET. The report evaluates no specific test and stresses that results depend on how likely amyloid was before testing and must be read in the full clinical context.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Schindler, S. E., Galasko, D., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez-Calvet, M., et al. (2024). Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. Nature Reviews Neurology. https://doi.org/10.1038/s41582-024-00977-5

Vancouver

Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suárez-Calvet M, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. Nature Reviews Neurology. 2024. doi:10.1038/s41582-024-00977-5. PMID: 38866966.

BibTeX

@article{schindler2024-38866966,
  author  = {Schindler, S. E. and Galasko, D. and Pereira, A. C. and Rabinovici, G. D. and Salloway, S. and Suárez-Calvet, M. and Khachaturian, A. S. and Mielke, M. M. and Udeh-Momoh, C. and Weiss, J. and Batrla, R. and Bozeat, S. and others},
  title   = {{Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease}},
  journal = {Nature Reviews Neurology},
  year    = {2024},
  doi     = {10.1038/s41582-024-00977-5},
  pmid    = {38866966},
  url     = {https://doi.org/10.1038/s41582-024-00977-5}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

An expert workgroup of the Global CEO Initiative on Alzheimer's Disease set minimum accuracy targets for blood tests of amyloid, judged against amyloid PET. A blood test used to triage people before a confirmatory PET or spinal-fluid test should reach at least 90% sensitivity with at least 85% specificity in primary care (75–85% in specialist care, depending on follow-up testing); a blood test used on its own should match spinal-fluid tests, at about 90% for both. The report evaluates no specific test and stresses that results depend on how likely amyloid was before testing and must be read in the full clinical context.

Study details

How this study scored 62/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 61 of the 98 points it could be judged on, which is 62 of 100. Total 62 of 100.61 of the 98 points we could judge = 62 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 61 of the 98 points we could judge it on, which is 62 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Nature Reviews Neurology)
Journal's citation record 3 / 4 Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 294 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 73.5 citations a year over 4 year(s) since 2024
Impact for its field and year 5 / 6 Cited 30.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 46 other studies in this library
Still being cited 4 / 4 Cited 294 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 29 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38866966)
Free to read — / 2 Access not recorded — left out of this score
Points 61 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 61 of the 98 points we could judge it on is 62 out of 100.
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 45.

Later studies that cite this one

46 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →